Do you want to read an article? Please log in or register.
Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab
Adv Ther
Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Korsiak J, Lefebvre P, Kerner C, Pilon D
doi: 10.1007/s12325-024-02942-6
Inflammatory Bowel Disease
Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab
Adv Ther
Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Lefebvre P, Kerner C, Pilon D
doi: 10.1007/s12325-024-02963-1
Inflammatory Bowel Disease
Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study
J Crohns Colitis
Bokemeyer B, Plachta-Danielzik S, Gilman E, Howaldt S, Mohl W, Efken P, Ehehalt R, Kahl M, Krause T, Trentmann L, Lügering A, Schnoy E, Jochum C, Hartmann P, Schreiber S
doi: 10.1093/ecco-jcc/jjaf052
Inflammatory Bowel Disease
Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study
Am J Gastroenterol
Solitano V, Narula N, Ma C, Nanayakkara A, Suarez KE, Zoughlami A, Guizzetti L, Bessissow T, Jairath V
doi: 10.14309/ajg.0000000000003212
Inflammatory Bowel Disease
Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data
Inflamm Bowel Dis
Ertem FU, Rivers CR, Ghaffari AA, Watson AR, Tang G, Schwartz M, Johnston E, Barrie A, Harrison J, Dueker JM, Hartman D, Binion DG
doi: 10.1093/ibd/izae137
Inflammatory Bowel Disease
Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey
J Crohns Colitis
Fiorino G, Walsh A, Adamina M, Barreiro-Acosta M, Ali MP, Bortlik M, Burisch J, Dignass A, Drobne D, Faiz O, Ferrante M, Fierens L, Godny L, Gojdicova A, Iacucci M, Jӓghult S, Karmiris K, Kirchgesner J, Restellini S, Rosini F, Shouval D, Van Deen W, Yanai H, Zagórowicz E, Fidalgo C, European Crohn’s Colitis Organisation
doi: 10.1093/ecco-jcc/jjaf094
Inflammatory Bowel Disease
Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data
BMC Gastroenterol
Dignass A, Teich N, Kaiser S, Sünwoldt J, Dünweber C, Weinhold I, Borchert J, Kudernatsch R
doi: 10.1186/s12876-025-04022-7
RECOMMENDED
Inflammatory Bowel Disease
Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study of GETECCU
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis
Fuentes-Valenzuela E, Bastón-Rey I, García-Alonso FJ, Elosua A, Zabalza San Martín L, Leo Carnerero E, Garcia de la Filia I, Pedraza Pérez A, Sáiz Chumillas RM, Pascual Oliver A, Muñoz Villafranca C, Moreno V, Suárez Ferrer C, Molina G, Ferreiro-Iglesias R, Vega Villaamil P, Gardeazábal Mateos D, Segarra-Ortega JX, Garrido Marín A, Doallo AI, Alonso-Galán H, Brunet-Mas E, Jimenez García N, López Romero-Salazar F, Velayos B, Carballo-Folgoso L, Pérez Santamaría C, Mata Román L, Núñez Ortiz A, Barrio J, Barreiro-de Acosta M, Gutiérrez-Casbas A, Young GETECCU group
doi: 10.1093/ecco-jcc/jjaf058
Inflammatory Bowel Disease
Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety
BMC Gastroenterol
Parra RS, de Sá Brito Fróes R, Magro DO, da Costa Ferreira S, de Mello MK, de Azevedo MFC, Damião AOMC, de Sousa Carlos A, Barros LL, de Miranda MLQ, Vieira A, Sales MPM, Zabot GP, Cassol OS, Tiburcio Alves AJ Jr, Lubini M, Machado MB, Flores C, Teixeira FV, Coy CSR, Zaltman C, Chebli LA, Sassaki LY, Féres O, Chebli JMF
doi: 10.1186/s12876-025-03656-x